Quality-by-Design Concepts to Improve Nanotechnology-Based Drug Development

Area of Science:

• Pharmaceutical Sciences
• Nanotechnology
• Drug Development

Background:

• Nanomedicine offers unique advantages over conventional drugs due to properties like targeted delivery.
• The increasing use of nano-sized formulations presents regulatory and development challenges.
• Unique properties of nanomaterials necessitate controlled and consistent manufacturing approaches.

Purpose of the Study:

• To review challenges in applying Quality by Design (QbD) to nanoparticle-based drug products.
• To discuss defining appropriate quality parameters for successful nanomedicine development.
• To highlight the importance of QbD and critical quality attributes (CQAs) in nanomedicine.

Main Methods:

• Review of existing literature on QbD principles and nanomedicine development.
• Discussion of regulatory pathways and challenges for nano-based formulations.
• Focus on identifying and specifying CQAs for nanomaterial-based products and intermediates.

Main Results:

• Quality by Design (QbD) methodology provides a framework for successful nano-based formulation development.
• Identification of critical quality attributes (CQAs) is crucial for ensuring product consistency.
• Addressing QbD challenges facilitates regulatory approval and market entry for nanomedicines.

Conclusions:

• Quality by Design (QbD) is essential for the controlled development of nanoparticle drug products.
• Defining and specifying critical quality attributes (CQAs) are fundamental to nanomedicine success.
• Implementing QbD principles supports the growth and advancement of nanomaterials in pharmaceuticals.